ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Atorvastatin

Also written as “atorvastatin”, “Atorvastatin 20 mg” and “Comparator: atorvastatin”.

Its studies are mostly in Hypercholesterolemia · Dyslipidemias · Hyperlipidemias · Diabetes Mellitus, Type 2 · Cardiovascular Diseases, led by 22 companies.

Drug pageAtorvastatin: every studyMany companies study it; this page follows only the 105 they lead. All 640 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Aug 30, 2005105 company-led studies, 1 open or runningNext primary completion: Apr 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Viatrisits history only290 open or runningphase 4since Aug 30, 2005Aug 25, 2005none ahead
Organon200 open or runningphase 4since Apr 1, 2008Sep 23, 2004none ahead
Pfizerits history only160 open or runningphase 4since Sep 6, 2005Aug 22, 2005none ahead
Chong Kun Dang Pharmaceuticalits history only60 open or runningphase 4since Nov 16, 2009Nov 16, 2009none ahead
Dr. Reddy's Laboratoriesits history only60 open or runningphase 1since Jul 18, 2012Jul 18, 2012none ahead
GlaxoSmithKlineits history only60 open or runningphase 3since Dec 15, 2011Dec 11, 2006none ahead
Astellas Pharmaits history only30 open or runningphase 4since Dec 5, 2006Dec 5, 2006none ahead
Daiichi Sankyoits history only30 open or runningphase 4since Sep 16, 2008Sep 16, 2008none ahead
Midas Pharmaits history only20 open or runningphase 1since Jan 23, 2020Jan 23, 2020none ahead
Sun Pharmaceutical Industriesits history only20 open or runningphase 1since Dec 20, 2011Dec 20, 2011none ahead

Also a collaborator on its studies: Parexel, Pharma Medica Research, Merck, Regeneron Pharmaceuticals, MDS Pharma Services, Celerion, Sanofi and Basilea Pharmaceutica International.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Organon only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 3 studies since Sep 23, 2004.

  1. Nov 2, 2006Phase 3 study in Cardiovascular DiseasesNCT00395603 · 550 enrolled
  2. Jan 3, 2007Phase 3 study in HypercholesterolemiaNCT00418834 · 1,053 enrolled
  3. Sep 25, 2007Phase 3 study in HypercholesterolemiaNCT00535405 · 1,289 enrolled
  4. Oct 5, 2007Phase 3 study in Diabetes Mellitus, Type 2NCT00541697 · 648 enrolled
  5. Mar 31, 2008Phase 3 study in HypercholesterolemiaNCT00650689 · 122 enrolled
  6. Apr 1, 2008Phase 3 study in HypercholesterolemiaNCT00654095 · 146 enrolled
  7. Apr 1, 2008Phase 4 study in HypercholesterolemiaNCT00653796 · 148 enrolled
  8. Oct 29, 2008Phase 3 study in HypercholesterolemiaNCT00782184 · 250 enrolled
  9. Mar 26, 2009Phase 4 study in Primary HypercholesterolemiaNCT00871351 · 125 enrolled
  10. Jun 29, 2010Phase 3 study in HypercholesterolemiaNCT01154036 · 1,547 enrolled
  11. Jun 8, 20112 phase 3 studies in HypercholesterolemiaNCT01370603, NCT01370590
  12. May 29, 2015Phase 3 study in HypercholesterolemiaNCT02460159 · 135 enrolled
  13. Sep 14, 2015Phase 3 study in HypercholesterolemiaNCT02550288 · 309 enrolled
  14. Mar 6, 20193 phase 3 studiesNCT03884452, NCT03867318, NCT03867110

TargetBeta

HMGCR →read by rule
“HMG-CoA reductase inhibitor”ChEMBL 37, by rule

Other programs on HMGCR

ProgramCompanyFurthest phaseStudies
rosuvastatinruleAstraZenecaphase 4184
SimvastatinruleOrganonphase 4100
pitavastatinruleKowaphase 436

Studies

All 20 Organon leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03884452Hyperlipoproteinemia Type II3CompletedMay 24, 200150
NCT03867318Hypercholesterolemia3CompletedNov 16, 2001621
NCT03867110Hypercholesterolemia3CompletedJul 27, 2001628
NCT02550288Hypercholesterolemia3CompletedMay 30, 2016309
NCT02460159Hypercholesterolemia3CompletedDec 22, 2016135
NCT01370603Hypercholesterolemia3CompletedMay 2012328
NCT01370590Hypercholesterolemia3CompletedApr 2012406
NCT01154036Hypercholesterolemia3CompletedSep 20121,547
NCT00871351Primary Hypercholesterolemia4CompletedMay 1, 2010125
NCT00782184Hypercholesterolemia3CompletedSep 2010250
NCT00654095Hypercholesterolemia3CompletedJun 1, 2009146
NCT00653796Hypercholesterolemia4CompletedAug 1, 2004148
NCT00650689Hypercholesterolemia3CompletedDec 2004122
NCT00541697Diabetes Mellitus, Type 23CompletedSep 28, 2005648
NCT00535405Hypercholesterolemia3CompletedMar 20091,289
NCT00418834Hypercholesterolemia3CompletedOct 20081,053
NCT00395603Cardiovascular Diseases3TerminatedJun 2007550
NCT00110435Diabetes Mellitus, Type 23CompletedDec 20051,229
NCT00092716Hypercholesterolemia3CompletedApr 2003655
NCT00092690Hypercholesterolemia3CompletedMar 20041,902

How it is read

Names in the registry

  • “Atorvastatin”, 95 entries
  • “atorvastatin”, 36 entries
  • “Atorvastatin 20 mg”, 3 entries
  • “Comparator: atorvastatin”, 3 entries
  • “Atorvastatin 10 mg”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.